A detailed history of Fmr LLC transactions in Amylyx Pharmaceuticals, Inc. stock. As of the latest transaction made, Fmr LLC holds 1,157,988 shares of AMLX stock, worth $5.93 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,157,988
Previous 731,356 58.33%
Holding current value
$5.93 Million
Previous $2.76 Million 48.68%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 12, 2025

BUY
$3.0 - $4.15 $1.28 Million - $1.77 Million
426,632 Added 58.33%
1,157,988 $4.1 Million
Q4 2024

Feb 13, 2025

BUY
$2.94 - $7.03 $1.5 Million - $3.59 Million
510,355 Added 230.93%
731,356 $2.76 Million
Q3 2024

Nov 13, 2024

BUY
$1.65 - $3.24 $271,626 - $533,375
164,622 Added 291.99%
221,001 $716,000
Q2 2024

Aug 13, 2024

BUY
$1.62 - $2.71 $59,922 - $100,240
36,989 Added 190.76%
56,379 $107,000
Q1 2024

May 13, 2024

SELL
$2.71 - $19.57 $3.84 Million - $27.7 Million
-1,416,761 Reduced 98.65%
19,390 $55,000
Q4 2023

Feb 13, 2024

BUY
$12.07 - $18.46 $12 Million - $18.4 Million
997,465 Added 227.38%
1,436,151 $21.1 Million
Q3 2023

Nov 13, 2023

SELL
$18.08 - $23.45 $186,151 - $241,441
-10,296 Reduced 2.29%
438,686 $8.03 Million
Q2 2023

Aug 11, 2023

BUY
$20.98 - $31.42 $9.27 Million - $13.9 Million
441,752 Added 6109.99%
448,982 $9.68 Million
Q1 2023

May 11, 2023

SELL
$27.71 - $40.93 $15,905 - $23,493
-574 Reduced 7.36%
7,230 $212,000
Q4 2022

Feb 13, 2023

BUY
$29.75 - $39.26 $222,173 - $293,193
7,468 Added 2222.62%
7,804 $288,000
Q3 2022

Nov 10, 2022

SELL
$17.15 - $30.92 $2.09 Million - $3.78 Million
-122,107 Reduced 99.73%
336 $9,000
Q2 2022

Aug 12, 2022

BUY
$6.85 - $19.93 $235,078 - $683,957
34,318 Added 38.94%
122,443 $2.36 Million
Q1 2022

May 13, 2022

BUY
$12.85 - $32.9 $1.13 Million - $2.9 Million
88,125 New
88,125 $1.13 Million

Others Institutions Holding AMLX

About Amylyx Pharmaceuticals, Inc.


  • Ticker AMLX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,533,200
  • Market Cap $300M
  • Description
  • Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...
More about AMLX
Track This Portfolio

Track Fmr LLC Portfolio

Follow Fmr LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.